By Timothy S. Donahue

Top Takeaways:

• Strategic pivot: Ispire shifts deeper into nicotine and compliance technology markets
• FDA momentum: Company says recent flavored vape authorizations validate age-gating strategy
• Manufacturing edge: Malaysia operations positioned as tariff advantage over China

Ispire Technology Inc. says the reset phase of its business is over and the next chapter focuses on nicotine, compliance technology, and what executives believe could be a major opening for flavored vape approvals in the United States.

Reporting fiscal third-quarter 2026 results, the company cited stabilizing operations, improving liquidity, and growing interest in its age-gating technology following recent U.S. Food and Drug Administration authorizations for restricted-access flavored vapor products.

“This quarter marked a turning point for Ispire,” said Michael Wang, co-chief executive officer and president of Aspire North America. “Our business has stabilized. Our operating model is sharper and more disciplined, and we ended the quarter with $18 million in cash, up $468,000 sequentially.”

Wang called the sequential cash growth “one of the clearest signs of progress” and said the company believes it can achieve cash-flow positivity in the second half of calendar year 2026.

Revenue for the quarter totaled $18.7 million, down from $26.2 million a year earlier and $20.3 million sequentially. Executives emphasized that the decline reflected both seasonal Chinese New Year factory shutdowns and the company’s move away from lower-quality cannabis revenue toward regulated nicotine and compliance technologies.

“The transition we set out to make is behind us,” Wang said. “Now we are executing against a phased growth roadmap, multiple catalysts, each tied to billion-dollar markets where we have clear competitive advantages.”

Malaysia is central to that strategy. Wang described the company’s manufacturing operation there as “one of the most strategically important developments in the company’s history,” citing what he said is an estimated 25% tariff advantage over China in the roughly $73 billion global vape market.

“In addition, Malaysia provides us with an estimated 25% tariff advantage over China, giving us both economic and strategic leverage,” Wang said. “This is both a manufacturing milestone and a structural advantage that we believe can support margin improvement, customer acquisition, and long-term market relevance.”

The company also said that the supply of nicotine pouches to global customers began in April 2026, while its Vapor ODM initiative is expected to launch in July, initially targeting small and midsized brands before pursuing larger partnerships in 2027.

But the biggest investor focus during the earnings call centered on age-gating technology and the recent FDA movement regarding flavored vapor products.

Wang repeatedly cited FDA authorization of flavored products tied to device-access restrictions as validation of Ispire’s IKE Tech platform. “Age-Gating is the only way to get flavored approval,” Wang said during the question-and-answer session.

Responding to analysts’ questions about FDA expectations, Wang said Ispire’s system was specifically designed for continuous authentication rather than one-time verification. “Yes, we do have that built into our solution,” Wang said. “From day 1, that was the key differentiation between our technology and other solutions out there.”

He criticized older systems that allow devices to remain active indefinitely after the initial age verification. “So that’s why from day 1, our solution was continuous authentication and that proved to be very important to regulators, not only with the FDA, but outside the U.S. as well,” Wang said.

Wang also suggested that recent FDA actions have accelerated discussions with vape manufacturers seeking regulatory pathways for flavored products. “In the last 48 hours, up to 72 hours, the ground was moving per se,” he said. “The immediate approval of the 4 additional SKUs for glass sent a strong signal to the industry.”

According to Wang, some companies are now discussing integrating Ispire’s technology into supplemental premarket tobacco product application (PMTA) filings. “We actually have even moved one step further discussing using our technology in some of their existing PMTAs through a so-called supplemental PMTA to accelerate the approval of their flavored products,” he said.

He added that the company has seen a sharp increase in interest from industry participants following the FDA decisions. “Yesterday, put it this way, I worked for 17 hours,” Wang said. “That’s much longer than my typical day of 12 hours.”

The company is also developing G-Mesh glass technology, which Wang said is attracting interest from major tobacco companies in what he described as a global legal market valued at $24 billion or more.

On the financial side, CFO Jie Yu said margins were pressured by about $2.2 million in one-time product returns from legacy cannabis customers the company no longer serves. “We view those returns as part of final cleanup associated with our strategic repositioning,” Yu said.

Operating expenses, excluding credit losses, fell 36% year over year, which Yu said reflected “sustained cost discipline and a more focused operating structure.”

Ispire’s earnings call underscored how quickly age-verification technology is becoming intertwined with the regulatory future of flavored vapor products, particularly as companies position themselves around FDA expectations for youth-access prevention and compliance controls.